Evidence map›Paper›PMID 40006906›Full record

ReviewViruses2025

Strategies for the Viral Exploitation of Nuclear Pore Transport Pathways.

Xin Zhang, Keesiang Lim, Yujia Qiu, Masaharu Hazawa, Richard W Wong

Abstract readReview
In one paragraph

Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xin ZhangDivision of Nano Life Science, Graduate School of Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan.
Keesiang LimWPI-Nano Life Science Institute, Kanazawa University, Kanazawa 920-1192, Japan.ORCID 0000-0001-9330-5783
Yujia QiuDivision of Nano Life Science, Graduate School of Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan.
Masaharu HazawaWPI-Nano Life Science Institute, Kanazawa University, Kanazawa 920-1192, Japan.ORCID 0000-0003-0342-9016
Richard W WongDivision of Nano Life Science, Graduate School of Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan.

Funding

JSPS 22H05537, 22H02209, 23H04278, 24H01276, 24K18449,JST CREST JPMJCR22E3
6 · The paper itself

Abstract

Viruses frequently exploit the host's nucleocytoplasmic trafficking machinery to facilitate their replication and evade immune defenses. By encoding specialized proteins and other components, they strategically target host nuclear transport receptors (NTRs) and nucleoporins within the spiderweb-like inner channel of the nuclear pore complex (NPC), enabling efficient access to the host nucleus. This review explores the intricate mechanisms governing the nuclear import and export of viral components, with a focus on the interplay between viral factors and host determinants that are essential for these processes. Given the pivotal role of nucleocytoplasmic shuttling in the viral life cycle, we also examine therapeutic strategies aimed at disrupting the host's nuclear transport pathways. This includes evaluating the efficacy of pharmacological inhibitors in impairing viral replication and assessing their potential as antiviral treatments. Furthermore, we emphasize the need for continued research to develop targeted therapies that leverage vulnerabilities in nucleocytoplasmic trafficking. Emerging high-resolution techniques, such as advanced imaging and computational modeling, are transforming our understanding of the dynamic interactions between viruses and the NPC. These cutting-edge tools are driving progress in identifying novel therapeutic opportunities and uncovering deeper insights into viral pathogenesis. This review highlights the importance of these advancements in paving the way for innovative antiviral strategies.

Indexed as

Active Transport, Cell NucleusHost-Pathogen InteractionsNuclear PoreVirus DiseasesVirusesVirus Physiological PhenomenaAnimalsAntiviral AgentsCell NucleusHumansNuclear Pore Complex ProteinsVirus ReplicationAntiviral AgentsNuclear Pore Complex Proteinsantiviral drugcentral pluggene gatingHIVHS-AFMkaryopherinnuclear transport inhibitornucleoporinsSARS-CoV-2spider cobwebsuper enhancer

Identifiers

PMID40006906
PMCPMC11860923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.